Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

W N Hait

Showing results (51-60 of 68) with videos related to

Pageof 7
Sort By:
Journal of the American Academy of Dermatology|January 1, 1987
Combined total body electron beam irradiation and chemotherapy for mycosis fungoidesI M Braverman, N B Yager, M Chen, et al.
Biochemical and Biophysical Research Communications|December 3, 1999
Treatment of multidrug resistant (MDR1) murine leukemia with P-glycoprotein substrates accelerates the course of the diseaseJ M Yang, G Y Yang, D J Medina, et al.
Cancer Research|May 15, 1993
Phosphorylation of elongation factor 2 in normal and malignant rat glial cellsD M Bagaglio, E H Cheng, F S Gorelick, et al.
Biochemical Pharmacology|January 26, 1993
Terfenadine (Seldane): a new drug for restoring sensitivity to multidrug resistant cancer cellsW N Hait, J F Gesmonde, J R Murren, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 17, 1998
The expression of drug resistance gene products during the progression of human prostate cancerG F Sullivan, P S Amenta, J D Villanueva, et al.
British Journal of Cancer|July 17, 1999
Activity and regulation by growth factors of calmodulin-dependent protein kinase III (elongation factor 2-kinase) in human breast cancerT G Parmer, M D Ward, E J Yurkow, et al.
Cancer Research|August 14, 1999
DNA damage increases sensitivity to vinca alkaloids and decreases sensitivity to taxanes through p53-dependent repression of microtubule-associated protein 4C C Zhang, J M Yang, J Bash-Babula, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1996
Trifluoperazine as a modulator of multidrug resistance in refractory breast cancerJ R Murren, H J Durivage, A C Buzaid, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1989
Phase I trial of combined therapy with bleomycin and the calmodulin antagonist, trifluoperazineW N Hait, S Morris, J S Lazo, et al.
Cancer Research|October 15, 1990
The effect of calmodulin inhibitors with bleomycin on the treatment of patients with high grade gliomasW N Hait, T N Byrne, J Piepmeier, et al.
Pageof 7

Showing results (51-60 of 68) with videos related to

Sort By:
Pageof 7
Journal of the American Academy of Dermatology|January 1, 1987
Combined total body electron beam irradiation and chemotherapy for mycosis fungoidesI M Braverman, N B Yager, M Chen, et al.
Biochemical and Biophysical Research Communications|December 3, 1999
Treatment of multidrug resistant (MDR1) murine leukemia with P-glycoprotein substrates accelerates the course of the diseaseJ M Yang, G Y Yang, D J Medina, et al.
Cancer Research|May 15, 1993
Phosphorylation of elongation factor 2 in normal and malignant rat glial cellsD M Bagaglio, E H Cheng, F S Gorelick, et al.
Biochemical Pharmacology|January 26, 1993
Terfenadine (Seldane): a new drug for restoring sensitivity to multidrug resistant cancer cellsW N Hait, J F Gesmonde, J R Murren, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 17, 1998
The expression of drug resistance gene products during the progression of human prostate cancerG F Sullivan, P S Amenta, J D Villanueva, et al.
British Journal of Cancer|July 17, 1999
Activity and regulation by growth factors of calmodulin-dependent protein kinase III (elongation factor 2-kinase) in human breast cancerT G Parmer, M D Ward, E J Yurkow, et al.
Cancer Research|August 14, 1999
DNA damage increases sensitivity to vinca alkaloids and decreases sensitivity to taxanes through p53-dependent repression of microtubule-associated protein 4C C Zhang, J M Yang, J Bash-Babula, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1996
Trifluoperazine as a modulator of multidrug resistance in refractory breast cancerJ R Murren, H J Durivage, A C Buzaid, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1989
Phase I trial of combined therapy with bleomycin and the calmodulin antagonist, trifluoperazineW N Hait, S Morris, J S Lazo, et al.
Cancer Research|October 15, 1990
The effect of calmodulin inhibitors with bleomycin on the treatment of patients with high grade gliomasW N Hait, T N Byrne, J Piepmeier, et al.
Pageof 7